Pharmacological Inhibition of the map2k7 Kinase in Human Disease

Authors

H Daniel Lacorazza

Publication Date

1-1-2024

Journal

Frontiers in Oncology

DOI

10.3389/fonc.2024.1486756

PMID

39717752

PMCID

PMC11663940

PubMedCentral® Posted Date

12-9-2024

PubMedCentral® Full Text Version

Post-print

Abstract

The MAP2K7 signaling pathway activates the c-Jun NH2-terminal protein kinase (JNK) in response to stress signals, such as inflammatory cytokines, osmotic stress, or genomic damage. While there has been interest in inhibiting JNK due to its involvement in inflammatory processes and cancer, there is increasing focus on developing MAP2K7 inhibitors to enhance specificity when MAP2K7 activation is associated with disease progression. Despite some progress, further research is needed to fully comprehend the role of MAP2K7 in cancer and assess the potential use of kinase inhibitors in cancer therapy. This review examines the role of MAP2K7 in cancer and the development of small-molecule inhibitors.

Keywords

MAP2K7, kinase inhibitors, T-ALL, leukemia, mitogen-activated protein kinase kinase 7, cancer

Published Open-Access

yes

Recommended Citation

H Daniel Lacorazza, "Pharmacological Inhibition of the map2k7 Kinase in Human Disease" (2024). Faculty and Staff Publications. 5610.
https://digitalcommons.library.tmc.edu/baylor_docs/5610